Divya Gupta et al. JCHF 2013;1:

Slides:



Advertisements
Similar presentations
03/06/021 K June /06/ Vascular Smooth Muscle Cells Endothelium Neural Other Tissues Intrinsic Factors Regulation of Flow (Q)
Advertisements

CHMI E.R. Gauthier, Ph.D. 1 CHMI 2227E Biochemistry I Enzymes: - Inhibition.
By the end of this lecture you will be able to: Recognize the role of NO in cellular communication. Classify the different NOS available Expand on its.
Cell-toCell COMMUNICATION
Cardiovascular pathophysiology III
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cirrhotic Cardiomyopathy J Am Coll Cardiol. 2010;56(7):
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiovascular Abnormalities in Sickle Cell Disease.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Myocardial Microvascular Inflammatory Endothelial.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Role for peroxynitrite in the inhibition of prostacyclin.
Revised curriculum (1) December 16 (Tuesday) Second messengers
Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Role of the Natriuretic Peptide System in Cardiorenal.
Date of download: 9/18/2016 From: The Cardiomyopathy of Overload: An Unnatural Growth Response in the Hypertrophied Heart Ann Intern Med. 1994;121(5):
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Coronary endothelial dysfunction in the insulin-resistant.
Polymorphisms in endothelial nitric oxide synthase and atherogenesis
Enzyme linked - plasma membrane surface and cytoplasmic - receptors guanylyl cyclase.
Figure Legend: From: Immune Modulation by Volatile Anesthetics
Atrial Natriuretic Peptides [ANP]
From: Nitric Oxide: A Physiologic Messenger
DRUGS Acting OnParacrine Autocrine Mediators
Figure 1 Mechanisms of action of novel therapeutics for heart failure
Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.
Metabolism of red blood cells and white blood cells
Volume 4, Issue 3, Pages (June 2006)
Signal trasduction via cAMP
The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors  Tobias S. Köhler,
HFpEF, a Disease of the Vasculature: A Closer Look at the Other Half
Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model  Eric S. Weiss, MD,
Volume 151, Issue 2, Pages (February 2017)
Role of redox signaling and poly (adenosine diphosphate-ribose) polymerase activation in vascular smooth muscle cell growth inhibition by nitric oxide.
The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.
Physiology of the endothelium
Vascular endothelial dysfunction in cirrhosis
Daniel A. Langer, Vijay H. Shah  Journal of Hepatology 
Atrial Natriuretic Peptides [ANP]
Antoni Bayés-Genís JCHF 2015;3:
Volume 151, Issue 2, Pages (February 2017)
NITRATES 20/01/2011.
Evaluation of the microcirculation in vascular disease
Lipid Soluble Hormone.
Mechanisms of rIPC. Mechanisms of rIPC. AP-1, activator protein-1; cGMP, cyclic guanosine monophosphate; CGRP, calcitonin gene-related peptide; COX2, cyclooxygenase.
Diabetes and peripheral vascular disease
ORGANIC NITRATES February 2017.
Yasuko Iwakiri, Vijay Shah, Don C. Rockey  Journal of Hepatology 
The sources of oxidative stress in the vessel wall
Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.
The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.
Guo-Wei He, MD, DSc, David P. Taggart, FRCS 
Thomas Quaschning, Jan Galle, Christoph Wanner
Juan-Carlos García-Pagán, Jorge Gracia-Sancho, Jaume Bosch 
Margus Annuk, Mihkel Zilmer, Bengt Fellström
Volume 70, Issue 10, Pages (November 2006)
Eberhard Schulz, and Thomas Münzel JACC 2008;52:
Mary P. Kotlarczyk, PhD, Marie Billaud, PhD, Benjamin R
Specific signal transduction mechanisms
Evaluation and Medical Management of Erectile Dysfunction
Constantijn Franssen et al. JCHF 2016;4:
Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies  Ben M Tsai, MD, Meijing Wang, MD, Mark W Turrentine,
Mechanism of action for pulmonary arterial hypertension medications.
Figure 4 NOS–NO pathway and therapeutic targets
Hypertension and Cerebrovascular Dysfunction
Constantijn Franssen et al. JCHF 2016;4:
Nat. Rev. Cardiol. doi: /nrcardio
Biology of endothelin receptors in the collecting duct
Postulated impact of SLE on endothelial nitric oxide (NO) synthase activity and endothelial nitric oxide synthase (eNOS) uncoupling. Postulated impact.
Evaluation and Medical Management of Erectile Dysfunction
Jurgen Schnermann, Josephine P. Briggs  Kidney International 
Thomas Münzel et al. JACC 2017;70:
Cell Signaling II.
Compounds acting on pathogenic pathways of pulmonary arterial hypertension. Compounds acting on pathogenic pathways of pulmonary arterial hypertension.
ENDOTHELIAL DYSFUNCTION(ED) in ERECTILE DYSFUNCTION(ED) ED=ED
Presentation transcript:

Divya Gupta et al. JCHF 2013;1:183-191 Tolerance and Pseudotolerance With Nitrate Therapy Nitrate use leads to neurohormonal activation, which results in intravascular expansion through increased sodium and water retention (pseudotolerance). Later during therapy, changes in endothelial and smooth muscle cells function resulting in vascular dysfunction (tolerance). These changes include: 1) activation of NADPH oxidase by angiotensin II through protein kinase C, which in turn results in superoxide (O2–) production; superoxide results in vasoconstriction through endothelin-1 and protein kinase C; 2) protein kinase C directly inhibits nitric oxide synthase; 3) reduced expression of GTP-cyclohydrolase and peroxynitrite-induced oxidation of tetrahydrobiopterin causes limited tetrahydrobiopterin availability, which in turn causes uncoupling of endothelial nitric oxide synthase, resulting in superoxide production and nitric oxide anions (NO–); nitric oxide anions through peroxynitrite cause inhibition of prostacyclin synthase resulting in reduced prostacyclin levels; 4) impaired bioactivation of nitroglycerin (NTG) caused by inhibition of aldehyde dehydrogenase results in O2– production, which in turn inhibits smooth muscle soluble guanylate cyclase both directly and through peroxynitrite; and 5) cyclic-guanosine monophosphate (cGMP) vasodilatory properties are diminished secondary to cGMP inactivation by phosphodiesterases and low cGMP production because of the inhibition of soluble guanylate cyclase. Divya Gupta et al. JCHF 2013;1:183-191 American College of Cardiology Foundation